Skip to main content
HCPCS J0750 · Level II · Part B drug

HCPCS J0750: Emtricitabine 200mg and tenofovir disoproxil fumarate 300mg, oral, fda approved

Reviewed by QuickIntell RCM Editorial Team · Last reviewed

Data effective
Data currency: ASP payment limits October 2026 (effective October 1, 2026); MUE and NCCI edits 2026 Q4 (effective October 1, 2026); OPPS Addendum B July 2026 (effective July 1, 2026). Next CMS release: January 1, 2027 (ASP, MUE, NCCI and OPPS quarterly updates).

Key facts for J0750

Billing unit
200 mg/300 mg
Hiv prep, ftc/tdf 200/300mg
ASP payment limit
$0.451
October 2026; -0.4% vs July 2026
Practitioner MUE
none published
CMS publishes no MUE for this code
OPPS status
SI K
APC 0806
NCCI exposure
no PTP pairs
Coverage articles
0
none list this code

TL;DR

HCPCS J0750 is the Level II code for Emtricitabine 200mg and tenofovir disoproxil fumarate 300mg, oral, fda approved, billed per 200 mg/300 mg. The Medicare Part B ASP payment limit for October 2026 is $0.451 per billing unit, down 0.4% from July 2026. Under OPPS it carries status indicator K in APC 0806. Oral drugs under Part B are payable only in the specific statutory categories (for example oral anticancer or antiemetic drugs with a self-administration exception), so the diagnosis and the regimen must match that category. No current Billing and Coding Article lists J0750, so coverage follows the FDA label, compendia and any applicable NCD.

Medicare Part B payment limit (ASP)

CMS sets the Part B payment limit for J0750 at $0.451 per 200 mg/300 mg for October 2026, derived from manufacturer average sales price plus 6%, compared with $0.453 in July 2026. Beneficiary coinsurance is 0%.

ASP payment limits for J0750
QuarterPayment limitPerCoinsurance
October 2026$0.451200 mg/300 mg0%
July 2026$0.453200 mg/300 mg—
CMS note: HIV PrEP drug

NDC to HCPCS billing-unit conversion

The October 2026 ASP crosswalk lists no NDC for J0750. Report the NDC from the product label and confirm the units conversion from the HCPCS descriptor (Emtricitabine 200mg and tenofovir disoproxil fumarate 300mg, oral, fda approved).

Medically Unlikely Edits (MUE)

CMS does not publish an MUE for J0750 in the 2026 Q4 tables. Some MUE values are confidential and applied without publication, so unit limits can still deny; document the dose and the units calculation on every claim.

NCCI edits and add-on relationships

No active practitioner PTP pair lists J0750 as a column-1 or column-2 code in v323r0. Drug supply codes are rarely bundled; the administration codes billed with them are where PTP edits usually apply.

J0750 is neither an add-on code nor a designated primary code in the 2026 Q4 NCCI add-on edit file.

Medicare coverage articles

No current Billing and Coding Article lists J0750 in its HCPCS table. Coverage then follows the drug's FDA label, compendia and any National Coverage Determination; check the Medicare Coverage Database before administering off-label.

Hospital outpatient (OPPS) status

In the July 2026 OPPS Addendum B, J0750 carries status indicator K and is assigned to APC 0806, with a published national unadjusted payment of $0.45. Status K means the drug is paid separately under OPPS at the ASP-based rate rather than packaged into the procedure.

Common denials for J0750 and how to prevent them

CARC 16 · M119

NDC missing, invalid or not matched to the HCPCS code

CARC 151 · N362

units billed exceed the MUE for the date of service

CARC 50 · N115

diagnosis not covered by the applicable coverage article or LCD

How QuickIntell checks J0750 before the claim leaves

QuickCode validates the NDC-to-unit conversion against the current ASP crosswalk, checks units against every published MUE setting and flags PTP and add-on conflicts on the same claim. QuickRCM routes CARC 16, 151 and 50 denials on drug lines with the matching coverage article attached so the appeal starts with evidence.

Explore QuickCodeExplore QuickRCMBook a meeting

Frequently asked questions — HCPCS J0750

What does HCPCS code J0750 describe?

J0750 is defined by CMS as "Emtricitabine 200mg and tenofovir disoproxil fumarate 300mg, oral, fda approved". Each billing unit represents 200 mg/300 mg, so the units reported on the claim must equal the dose administered divided by that unit.

What is the Medicare reimbursement for J0750 in October 2026?

The ASP-based payment limit is $0.451 per 200 mg/300 mg, with 0% beneficiary coinsurance. Medicare Administrative Contractors apply this limit; commercial payers use their own fee schedules. The July 2026 limit was $0.453.

Does J0750 have NCCI bundling edits?

No active practitioner PTP pairs list J0750 as a column-1 or column-2 code in the v323r0 release. Unit limits (MUE) and medical-necessity coverage rules still apply.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-10-02. Verify against the primary file before billing or contracting decisions.

Disclaimer

This page is an operational reference compiled from CMS publications: the Medicare Part B drug payment limit and NDC crosswalk files, NCCI MUE and add-on edit tables, aggregate PTP statistics, OPPS Addendum B and the Medicare Coverage Database. Payment limits are Medicare national amounts; commercial and Medicaid payers differ. CPT codes are shown as numbers only; CPT descriptors are copyright AMA. Nothing here is legal, clinical or billing advice.